-
Je něco špatně v tomto záznamu ?
Prognostic Significance of Inflammation-based Scores in Pancreatic Cancer Patients Treated With Palliative Chemotherapy: A Single Institution Experience
M. Liberko, T. Sychra, M. Oliverius, R. Soumarová
Jazyk angličtina Země Řecko
Typ dokumentu časopisecké články
NLK
PubMed Central
od 2017
Europe PubMed Central
od 2017
Open Access Digital Library
od 2004-01-01
PubMed
39477392
DOI
10.21873/invivo.13758
Knihovny.cz E-zdroje
- MeSH
- albuminy aplikace a dávkování MeSH
- deoxycytidin analogy a deriváty aplikace a dávkování terapeutické užití MeSH
- dospělí MeSH
- fluoruracil aplikace a dávkování terapeutické užití MeSH
- gemcitabin MeSH
- irinotekan aplikace a dávkování terapeutické užití MeSH
- Kaplanův-Meierův odhad MeSH
- leukovorin aplikace a dávkování terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory slinivky břišní * farmakoterapie mortalita patologie MeSH
- neutrofily patologie MeSH
- oxaliplatin aplikace a dávkování terapeutické užití MeSH
- paclitaxel aplikace a dávkování MeSH
- paliativní péče * metody MeSH
- prognóza MeSH
- protokoly protinádorové kombinované chemoterapie * terapeutické užití MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- zánět * patologie farmakoterapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND/AIM: Inflammation-based prognostic scores have shown prognostic significance and have been associated with clinical outcomes in various types of cancer. Inflammation is known to promote tumor progression leading to reduced survival. In pancreatic cancer, systemic inflammation is common and contributes to its dismal prognosis. Although the prognosis of pancreatic cancer is improving with the introduction of new drugs, the prognostic indicators are still poorly understood. The present study aimed to evaluate inflammation-based prognostic scores in patients with metastatic pancreatic cancer receiving first-line chemotherapy. PATIENTS AND METHODS: A total of 43 patients with metastatic pancreatic cancer undergoing first-line chemotherapy (gemcitabine+nab-paclitaxel and mFOLFIRINOX) in our institution were analyzed. Baseline clinicopathological and pre-treatment laboratory data were collected. Survival was estimated using the Kaplan-Meier method and survival differences were evaluated using the log-rank test. RESULTS: In the whole cohort, we identified lymphocyte-to-monocyte ratio ≥3, systemic inflammatory response index <2.3, carcinoembryonic antigen <2.5, neutrophil-to-lymphocyte ratio <5, Memorial Sloane Kettering score <2, and prognostic index <2 as prognostic markers associated with improved overall survival in patients receiving first-line chemotherapy. CONCLUSION: The current analysis showed an association between inflammatory-based prognostic markers and overall survival in patients with metastatic pancreatic cancer treated in a real-world setting at a single institution.
3rd Faculty of Medicine Charles University Department of Oncology Prague Czech Republic
Department of General Surgery University Hospital Kralovske Vinohrady Prague Czech Republic
Department of Oncology University Hospital Kralovske Vinohrady Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25003579
- 003
- CZ-PrNML
- 005
- 20250206104427.0
- 007
- ta
- 008
- 250121s2024 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21873/invivo.13758 $2 doi
- 035 __
- $a (PubMed)39477392
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Liberko, Marián $u Department of Oncology, University Hospital Kralovske Vinohrady, Prague, Czech Republic; marian.liberko@fnkv.cz $u Third Faculty of Medicine, Charles University, Department of Oncology, Prague, Czech Republic
- 245 10
- $a Prognostic Significance of Inflammation-based Scores in Pancreatic Cancer Patients Treated With Palliative Chemotherapy: A Single Institution Experience / $c M. Liberko, T. Sychra, M. Oliverius, R. Soumarová
- 520 9_
- $a BACKGROUND/AIM: Inflammation-based prognostic scores have shown prognostic significance and have been associated with clinical outcomes in various types of cancer. Inflammation is known to promote tumor progression leading to reduced survival. In pancreatic cancer, systemic inflammation is common and contributes to its dismal prognosis. Although the prognosis of pancreatic cancer is improving with the introduction of new drugs, the prognostic indicators are still poorly understood. The present study aimed to evaluate inflammation-based prognostic scores in patients with metastatic pancreatic cancer receiving first-line chemotherapy. PATIENTS AND METHODS: A total of 43 patients with metastatic pancreatic cancer undergoing first-line chemotherapy (gemcitabine+nab-paclitaxel and mFOLFIRINOX) in our institution were analyzed. Baseline clinicopathological and pre-treatment laboratory data were collected. Survival was estimated using the Kaplan-Meier method and survival differences were evaluated using the log-rank test. RESULTS: In the whole cohort, we identified lymphocyte-to-monocyte ratio ≥3, systemic inflammatory response index <2.3, carcinoembryonic antigen <2.5, neutrophil-to-lymphocyte ratio <5, Memorial Sloane Kettering score <2, and prognostic index <2 as prognostic markers associated with improved overall survival in patients receiving first-line chemotherapy. CONCLUSION: The current analysis showed an association between inflammatory-based prognostic markers and overall survival in patients with metastatic pancreatic cancer treated in a real-world setting at a single institution.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory slinivky břišní $x farmakoterapie $x mortalita $x patologie $7 D010190
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a paliativní péče $x metody $7 D010166
- 650 12
- $a zánět $x patologie $x farmakoterapie $7 D007249
- 650 12
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a gemcitabin $7 D000093542
- 650 _2
- $a fluoruracil $x aplikace a dávkování $x terapeutické užití $7 D005472
- 650 _2
- $a deoxycytidin $x analogy a deriváty $x aplikace a dávkování $x terapeutické užití $7 D003841
- 650 _2
- $a paclitaxel $x aplikace a dávkování $7 D017239
- 650 _2
- $a irinotekan $x aplikace a dávkování $x terapeutické užití $7 D000077146
- 650 _2
- $a leukovorin $x aplikace a dávkování $x terapeutické užití $7 D002955
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a oxaliplatin $x aplikace a dávkování $x terapeutické užití $7 D000077150
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a neutrofily $x patologie $7 D009504
- 650 _2
- $a albuminy $x aplikace a dávkování $7 D000418
- 650 _2
- $a senioři nad 80 let $7 D000369
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Sychra, Tomáš $u Third Faculty of Medicine, Charles University, Department of Oncology, Prague, Czech Republic $u Department of General Surgery, University Hospital Kralovske Vinohrady, Prague, Czech Republic
- 700 1_
- $a Oliverius, Martin $u Third Faculty of Medicine, Charles University, Department of Oncology, Prague, Czech Republic $u Department of General Surgery, University Hospital Kralovske Vinohrady, Prague, Czech Republic
- 700 1_
- $a Soumarová, Renata $u Department of Oncology, University Hospital Kralovske Vinohrady, Prague, Czech Republic $u Third Faculty of Medicine, Charles University, Department of Oncology, Prague, Czech Republic
- 773 0_
- $w MED00175831 $t In Vivo $x 1791-7549 $g Roč. 38, č. 6 (2024), s. 2782-2794
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39477392 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206104422 $b ABA008
- 999 __
- $a ok $b bmc $g 2263371 $s 1239586
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 38 $c 6 $d 2782-2794 $e - $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
- LZP __
- $a Pubmed-20250121